Integrated Diagnostics (IDHC) investor relations material

Executive summary

• Achieved 31% year-over-year revenue growth in Q1 2026 to EGP 2.1 billion, withstanding seasonal impacts from Ramadan and Eid and strong expansion across Egypt, Jordan, Saudi Arabia, and Nigeria.

• Net profit surged 78% year-over-year to EGP 437 million; adjusted net profit up 36% to EGP 292 million, with a stable margin of 14%.

• Test volumes increased 22% year-over-year to 10.4 million; average revenue per test rose 7%.

• Continued investment in network expansion, radiology, specialized diagnostics, and regional footprint, with 153 new branches added year-over-year.

• Egypt remained the main revenue contributor, with stable progress in Jordan, turnaround in Nigeria, and ramp-up in Saudi Arabia.

Financial highlights

• Gross profit grew 28% year-over-year to EGP 807 million; gross margin was 38.9%.

• EBITDA rose 23% to EGP 611 million, with a margin of 29.5%.

• Net profit margin reached 21.1%; adjusted net profit margin was 14.1%.

• Cost of goods sold rose 33% in line with higher activity and branch expansion; raw materials as share of revenue declined to 18.7%.

• SG&A expenses increased 32% to EGP 350 million, stable at 16.9% of revenue.

Outlook and guidance

• FY 2026 consolidated revenue expected to grow 39% year-over-year, with a budget of EGP 10 billion and gross profit margin of 43%.

• Saudi Arabia revenue expected at SAR 18 million for 2026, with 10 branches by year-end and plans to double the branch network.

• Flexibility to increase prices further if currency volatility persists; focus on price optimization, volume growth, and cost control.

• EBITDA margins expected to remain in the early thirties medium term.

• Continued monitoring of regional macroeconomic and geopolitical risks.